



Cancer center research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025

ORAL/RAPID ORAL ABSTRACT SESSIONS

| Abstract title | IU authors; presenter names are bolded | Date/time | Abstract | Abstract link |
|---|--|--------------------------------------|----------|---|
| Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy. | Shadia Jalal | June 1 11:15 a.m.- 12:45 p.m. CDT | 2513 | https://meetings.asco.org/abstracts-presentations/246271 |
| International medical graduates (IMGs) in leadership roles within academic oncology in the United States (US). | Hussain Rangoonwala | June 2 9:45 - 11:15 a.m. CDT | 9004 | https://meetings.asco.org/abstracts-presentations/246425 |
| Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. | Kathy Miller | June 2 3 -6 p.m. CDT | 501 | https://meetings.asco.org/abstracts-presentations/243640 |
| Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft - Oral Abstract Session | Rita Assi, moderator | June 2 3 -6 p.m. CDT | N/A | https://meetings.asco.org/2025-asco-annual-meeting/16374?presentation=244201#244201 |

EDUCATION SESSIONS/PANELS

| Session title | Presenter | Date/time | Session details | Session link |
|--|-----------------------------|--------------------------------------|-------------------|---|
| State-of-the-Art Updates in Colorectal Cancer: "Advances in Biomarker-Based Management of Metastatic Colorectal Cancer" | Anita Turk | June 2 9:45 - 11 a.m. CDT | Education session | https://meetings.asco.org/2025-asco-annual-meeting/16475?presentation=240927#240927 |
| Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening on a Global Scale: "End Lung Cancer Now: How to Engage Your Community to Promote Cancer Screening" | Nasser H. Hanna | June 2 11:30 a.m. – 12:45 p.m CDT | Education session | https://meetings.asco.org/2025-asco-annual-meeting/16514?presentation=240831#240831 |
| Refining Treatment for Patients With Metastatic Germ-Cell Tumors: "Pitfalls in the Management of Metastatic Germ-Cell Tumors" | Lawrence H. Einhorn | June 2 1:15 – 2:30 p.m CDT | Education session | https://meetings.asco.org/2025-asco-annual-meeting/16488?presentation=240651#240651 |
| Navigating Emerging Therapeutic Decisions in the Treatment of Small Cell Lung Cancer: Cases and Considerations - "Medical Oncologist Perspective" | Misty Shields | June 2 1:15 – 2:15 p.m CDT | Case-based panel | https://meetings.asco.org/2025-asco-annual-meeting/16510?presentation=240708#240708 |
| Current and Future Directions in Immunotherapies in Myeloma: "Is It Time to Include Bispecifics Into Upfront Therapy?" | Attaya Suvannasankha | June 3 8 – 9:15 a.m CDT | Education session | https://meetings.asco.org/2025-asco-annual-meeting/16577?presentation=240842#240842 |

SYMPOSIUM

| Abstract title | IU authors; presenter names are bolded | Date/time | Abstract number | Abstract link |
|---|--|----------------------------|-----------------|---|
| The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: ctDNA for Breast Cancer: It's Here—Are We Ready?: "Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial)." | Anna Maria Storniolo | June 1 4:30 - 6 p.m CDT | Abstract #1009 | https://meetings.asco.org/abstracts-presentations/248658 |

POSTER SESSIONS

| Abstract title | IU authors; presenter names are bolded | Date/time | Abstract number, poster number | Abstract link |
|---|--|-------------------------------|------------------------------------|---|
| A phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer: Big Ten Cancer Research Consortium G122-588. | Anita Turk | May 31 9 a.m. – 12 p.m CDT | Abstract #TPS3633 Poster #302a | https://meetings.asco.org/abstracts-presentations/252311 |
| A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187. | Anita Turk | May 31 9 a.m. – 12 p.m CDT | Abstract #4115 Poster Bd #405 | https://meetings.asco.org/abstracts-presentations/249899 |
| Prognostic value of inflammatory markers in glioblastoma: A meta-analysis of NLR and PLR stratified by cutoff values. | Omar Boges-Sosa | May 31 9 a.m. – 12 p.m CDT | Abstract #2067 Poster Bd #113 | https://meetings.asco.org/abstracts-presentations/248614 |
| Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from breast cancer. | Mateusz Opyrchal | May 31 9 a.m. – 12 p.m CDT | Abstract #TPS2088 Poster #134a | https://meetings.asco.org/abstracts-presentations/252217 |
| Does early versus late initiation of immunotherapy in extensive-stage small cell lung cancer affect survival outcomes? | Julian A. Marin-Acevedo, Misty D. Shields | May 31 1:30 - 4:30 p.m CDT | Abstract #8099 Poster #220 | https://meetings.asco.org/abstracts-presentations/249128 |
| Enhancing lung cancer surgical quality: Insights from a national quality improvement collaborative. | Anthony Yang | May 31 1:30 - 4:30 p.m CDT | Abstract #11140 Poster #479 | https://meetings.asco.org/abstracts-presentations/247431 |
| Impact of a collaborative care-based symptom intervention model on chemotherapy adherence in patients with breast cancer. | Kurt Kroenke | June 1 9 a.m. – 12 p.m CDT | Abstract #1543 Poster #296 | https://meetings.asco.org/abstracts-presentations/252104 |
| Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR T) therapy and other systemic anti-cancer therapy: A real-world data analysis. | Attaya Suvannasankha | June 1 9 a.m. – 12 p.m CDT | Abstract #7080 Poster #263 | https://meetings.asco.org/abstracts-presentations/246049 |
| MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). | Attaya Suvannasankha | June 1 9 a.m. – 12 p.m CDT | Abstract #TPS7566 Poster #132b | https://meetings.asco.org/abstracts-presentations/252588 |
| Estrogen receptor (ER) expression on circulating tumor cells (CTCs) and cell free DNA (cfDNA) mutational landscape in the PACE randomized phase II study. | Kathy Miller | June 2 9 a.m. – 12 p.m CDT | Abstract #1054 Poster #33 | https://meetings.asco.org/abstracts-presentations/248574 |
| Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)-positive advanced breast cancer (TBCRC 054). | Tarah J. Ballinger | June 2 9 a.m. – 12 p.m CDT | Abstract #1088 Poster #67 | https://meetings.asco.org/abstracts-presentations/248712 |
| TROP-2 expression in germ cell tumors (GCT). | Noah Richardson , Tareq Salous, Jennifer King, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra | June 2 9 a.m. – 12 p.m CDT | Abstract #5031 Poster #230 | https://meetings.asco.org/abstracts-presentations/246531 |
| Initiation of high dose chemotherapy at rising tumor markers compared with radiographic progression in patients with relapsed germ-cell tumors (GCT). | Rebecca Hassoun , Rafat Abonour, Tareq Salous, Jennifer King, Lawrence Einhorn, Nabil Adra | June 2 9 a.m. – 12 p.m CDT | Abstract #5033 Poster #232 | https://meetings.asco.org/abstracts-presentations/246533 |
| Limited changes in the CNS immune microenvironment in patients with breast cancer metastasis and capturing these changes using machine learning. | Na Tosha Gatson | June 2 9 a.m. – 12 p.m CDT | Abstract #1092 Poster #71 | https://meetings.asco.org/abstracts-presentations/248679 |
| Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). | Nabil Adra | June 2 9 a.m. – 12 p.m CDT | Abstract #5071 Poster #270 | https://meetings.asco.org/abstracts-presentations/246366 |
| The uTRACT registry: A single-arm, multicenter, prospective, and retrospective registry study to evaluate the real-world use of UGN-101 in participants with upper tract urothelial carcinoma (UTUC) in the United States. | Hristos Kaimakliotis | June 2 9 a.m. – 12 p.m CDT | Abstract #TPS4629 Poster #420a | https://meetings.asco.org/abstracts-presentations/253141 |
| Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC). | Jennifer King | June 2 9 a.m. – 12 p.m CDT | Abstract #4545 Poster #345 | https://meetings.asco.org/abstracts-presentations/248775 |
| NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. | Richard Zellars | June 2 9 a.m. – 12 p.m CDT | Abstract #TPS625 Poster #213a | https://meetings.asco.org/abstracts-presentations/252167 |
| Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study. | Mateusz Opyrchal | June 2 1:30 - 4:30 p.m CDT | Abstract #2575 Poster #222 | https://meetings.asco.org/abstracts-presentations/246750 |
| Comparison of outcomes for patients diagnosed with small cell lung cancer between a university and safety net hospital. | Julian Marin-Acevedo, Misty Shields | June 2 1:30 - 4:30 p.m CDT | Abstract #12077 Poster #97 | https://meetings.asco.org/abstracts-presentations/245196 |
| Supervised home-based exercise in patients with advanced non-small cell lung cancer (NSCLC) on maintenance immune checkpoint inhibitors (ICI). | Misty D. Shields, Greg A. Durm, Shadia I. Jalal, Rohan Maniar, Nasser H. Hanna, Tarah J. Ballinger | June 2 1:30 - 4:30 p.m CDT | Abstract #TPS12143 Poster #159b | https://meetings.asco.org/abstracts-presentations/252529 |
| RYZ101 (225Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study. | Kathy Miller | June 2 1:30 - 4:30 p.m CDT | Abstract #TPS3184 Poster #485b | https://meetings.asco.org/abstracts-presentations/252272 |

| PUBLICATION ONLY ABSTRACTS | | | |
|---|---|----------|---|
| Abstract title | IU authors (first author bolded) | Abstract | Abstract link |
| Evaluating inflammatory biomarkers as predictors of outcomes and immune-related adverse events (irAE) in the Big Ten Cancer Research Consortium (BTCRC) LUN16-081 phase II clinical trial. | Greg Durm , Shadia Jalal, Nasser Hanna | e20087 | https://meetings.asco.org/abstracts-presentations/250259 |
| Clinicogenomic features of non-small cell lung cancer patients with BRAF non-V600 mutations. | Bryan Schneider, Julian Marin-Acevedo, Misty Shields | e20519 | https://meetings.asco.org/abstracts-presentations/251956 |
| Clinical characteristics and outcomes of metastatic germ cell tumors with highly elevated human chorionic gonadotropin levels. | Noah Richardson , Rebecca Hassoun, Tareq Salous, Jennifer King, Nasser Hanna, Lawrence Einhorn, Nabil Adra | e17018 | https://meetings.asco.org/abstracts-presentations/247157 |
| Intensification of androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): Patterns of use and impact on outcomes from a large academic medical center. | Vidya Sree Dandu , Tareq Salous, Nabil Adra, Jennifer King | e17115 | https://meetings.asco.org/abstracts-presentations/247206 |
| Outcomes with trilaciclib versus granulocyte colony stimulating factor regarding chemotherapy-associated adverse events, dose reductions, and subsequent therapies in small cell lung cancer. | Julian Marin-Acevedo, Misty Shields | e20116 | https://meetings.asco.org/abstracts-presentations/249303 |
| Increasing lung cancer screening education among minoritized populations. | Catherine Sears, Francesca Duncan | e13740 | https://meetings.asco.org/abstracts-presentations/245516 |
| Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer. | Julian Marin-Acevedo, Misty Shields | e20125 | https://meetings.asco.org/abstracts-presentations/249322 |
| Progress in the management of primary and metastatic cardiac sarcoma: Advancing multidisciplinary care in an academic sarcoma center. | Suparna Clasen, Bharathi Muthusamy | e23568 | https://meetings.asco.org/abstracts-presentations/251448 |
| Towards personalized management of intraductal papillary mucinous neoplasms with multimodal artificial intelligence. | C. Max Schmidt, Fiona Kolbinger, Thi Thanh Thoa Tran | e16461 | https://meetings.asco.org/abstracts-presentations/251077 |
| Effect of a novel compound that covalently binds to the HPV16 E6 protein on proliferation of HPV-associated cervical and oropharyngeal cancer cells through p53 effector pathway activation. | Anne Rietz, Elliot Androphy | e15103 | https://meetings.asco.org/abstracts-presentations/250549 |
| Genomic alterations in metastatic renal cell carcinoma (RCC): Impact on prognosis and response to frontline therapy. | Jennifer King , Tareq Salous, Theodore Logan, Nabil Adra | e16529 | https://meetings.asco.org/abstracts-presentations/248960 |
| Prognostic value of the estrogen receptor alpha, ESR1, and aromatase expression in non-small cell lung cancer: A meta-analysis. | Patricia Silveyra | e20529 | https://meetings.asco.org/abstracts-presentations/251985 |
| Leveraging AI predictive models to develop thymic tumor-specific peptides mimicking COL17A1 alterations. | Patrick Loehrer Sr. | e20138 | https://meetings.asco.org/abstracts-presentations/249298 |
| Loss of ANPEP expression may promote the development of aggressive prostate cancer. | Asmaa El-Kenawi | e17052 | https://meetings.asco.org/abstracts-presentations/247169 |
| A multi-level qualitative exploration of factors influencing breast and cervical cancer screening uptake in Nepal. | Patrick Loehrer Sr. | e13858 | https://meetings.asco.org/abstracts-presentations/245573 |
| Cervical cancer treatment trajectories in a sample of cervical cancer patients in the Democratic Republic of the Congo: A retrospective descriptive study. | Jonas Ndeke , Jonathan Macy | e17519 | https://meetings.asco.org/abstracts-presentations/244058 |